<DOC>
	<DOCNO>NCT01801852</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness natural killer T ( NKT ) cell-based autologous adoptive immunotherapy subject metastatic , treatment-refractory breast cancer , glioma , hepatocellular carcinoma , squamous cell lung cancer , pancreatic cancer , colon cancer prostate cancer .</brief_summary>
	<brief_title>Autologous Natural Killer T Cells Infusion Treatment Cancer</brief_title>
	<detailed_description>A randomize control trial efficacy safety autologous natural killer T ( NKT ) cell infusion treatment advance cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>•Male female le 18 year age 80 year age . Life expectancy ≥ 24 week measure Eastern Cooperative Oncology Group ( ECOG ) performance status . Subjects must present one follow disease pathology : Breast Cancer , Glioma , Hepatocellular Cancer , Squamous Cell Lung Cancer , Pancreatic Cancer , Colon Cancer Prostate Cancer The pathology must assessable disease ( measurable CT scan MRI ) refractory standard treatment ( e.g. , chemotherapy , radiation , etc . ) Negative hepatitis B , hepatitis C , HIV , CMV . Subjects must present leukocyte count 3,000/μL platelet count 100,000/ μL . Subjects must present minimum hemoglobin level 10 . If female , subject surgically sterile ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) , post menopausal ( menses &gt; 12 month ) , use highefficiency method contraception implant , injectable , combination oral contraceptive , intrauterine device ( IUD ) sexual abstinence , vasectomized partner . If female childbearing potential , subject pregnant , breastfeed plan pregnancy study , negative pregnancy test screen visit . Able comprehend sign inform consent document comply requirement study . •No measurable malignant disease CT scan tumor marker . Life expectancy ≤ 24 week measure Eastern Cooperative Oncology Group ( ECOG ) performance status . Age le 18 year 80 year age . Documented/confirmed positive test hepatitis B , hepatitis C , HIV , CMV . Prior current history autoimmune disease . Pregnant lactating woman . Leukocyte count &lt; 3,000 /μL prior leukapheresis . Platelet count &lt; 100,000/μL prior leukapheresis . Hemoglobin level 10 . PTT ( prothrombin time ) &lt; 12 second &gt; 15 second . aPTT ( activate partial thromboplastin time ) &lt; 25 second &gt; 39 second . Failure refusal sign inform consent study . Culture fail meet specification study . Subject medical condition , opinion investigator , might significantly affect ability safely participate study affect conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>